2026-07-03
notable
Study Status, Study Design, Outcome Measures v4
Enrollment increased: 384 → 450 participants
Secondary endpoints7 to 8 entries
Time to Response (TTR)
2026-04-15
minor
Study Identification, Study Status v3
Study title+13 characters
[...] With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
2025-08-15
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-08→confirmed 2025-08-04
Study sitesdetails revised at 1 of 1 site
2025-07-31
minor
Study Status, Study Design, Outcome Measures, Eligibility v1
Start date2025-05→2025-08
Enrollment target540→384
Eligibility criteria+353 characters
Inclusion Criteria:
SignVoluntarily sign the informed consent form voluntarily and followcomply with the protocol requirements;
Age: ≥18 years old;
Expected survival time ≥3 months;
EpithelialHistologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, andor primary peritoneal cancer confirmed by histopathology or cytology;
Patients who had beenPreviously treated with a platinum-based regimensregimen and hadconfirmed provento have platinum-resistant relapserecurrence;
Patients with platinum-6 resistance hadPreviously received at1-3 most one linelines of systemic [...] [...]
Secondary endpoints8 to 7 entries
Overall survival (OS)
Primary endpoints1 to 2 entries
Overall survival (OS)
2025-05-20
minor
Original filing